

Product Description

Pioneering GTPase and Oncogene Product Development since 2010

KLF17 RABBIT PAB

Cat.#: S217096

Product Name: Anti-KLF17 Rabbit Polyclonal Antibody

Synonyms: ZNF393; Zfp393; RP4-675G8.1

UNIPROT ID: Q5JT82 (Gene Accession - BC049844)

Background: Krueppel-like factor 17 is a protein that in humans is encoded by the KLF17 gene. Transcription repressor that binds to the promoter of target genes and prevents their expression. Acts as a negative regulator of epithelial-mesenchymal transition and metastasis in breast cancer. Specifically binds the 5'-CACCC-3' sequence in the promoter of ID1, a key metastasis regulator in breast cancer, and repress its expression. May be a germ cell-specific transcription factor that plays important roles in spermatid differentiation and oocyte development.

Immunogen: Fusion protein of human KLF17

Applications: ELISA, IHC

Recommended Dilutions: IHC: 25-100; ELISA: 2000-5000

Host Species: Rabbit

Clonality: Rabbit Polyclonal

Isotype: Immunogen-specific rabbit IgG

Purification: Antigen affinity purification

Species Reactivity: Human

Constituents: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

Research Areas: Epigenetics and Nuclear Signaling

Storage & Shipping: Store at -20°C. Avoid repeated freezing and thawing



Product Description

Pioneering GTPase and Oncogene Product Development since 2010



Immunohistochemistry analysis of paraffin embedded Human colon cancer tissue using 217096(KLF17 Antibody) at a dilution of 1/30(Cytoplasm).



In comparision with the IHC on the left, the same paraffin-embedded Human colon cancer tissue is first treated with the fusion protein and then with 217096(Anti-KLF17 Antibody) at dilution 1/30.



The image on the left is immunohistochemistry of paraffinembedded Human thyroid cancer tissue using 217096(Anti-KLF17 Antibody) at a dilution protein and then with D221780(Anti-KLF17 of 1/30.



In comparision with the IHC on the left, the same paraffin-embedded Human thyroid cancer tissue is first treated with fusion Antibody) at dilution 1/30.